Price changes of neratinib/neratinib after entering medical insurance in 2026

Neratinib/neratinib (Neratinib), as a targeted drug for HER2-positive breast cancer, has demonstrated significant efficacy in clinical treatment in recent years. As the clinical application of neratinib gradually expands, more and more patients are paying attention to it. Especially since neratinib was included in medical insurance, its price has changed significantly, which is undoubtedly good news for the majority of patients.

The original drug neratinib has been launched in China and has recently been included in the Category B Drug List of the National Medical Insurance. Medical insurance reimbursement means that more patients who meet the indications can pay part of the cost through medical insurance, thereby reducing the burden of treatment. Taking the commonly used specification of neratinib40mg*180 tablets as an example, the price of the original drug is about RMB 7,000 per box. After being included in medical insurance, patients' out-of-pocket costs will be greatly reduced, making the use of neratinib more popular.

However, although neratinib has been included in medical insurance and has a preferential price, its reimbursement scope is still limited. According to the current medical insurance policy, medical insurance reimbursement for neratinib is limited to patients who meet specific indications, such as advanced or metastatic patients with HER2-positive breast cancer, and it needs to be used when other standard treatments are ineffective. Therefore, patients need to pass relevant medical records and examinations to ensure that they meet the conditions for medical insurance reimbursement.

With the inclusion of neratinib in medical insurance, it is expected that more patients will be able to receive this effective targeted therapy, especially those with more difficult financial conditions. Changes in drug prices have made high-priced drugs no longer a barrier to treatment and provided patients with more choices. However, although medical insurance policies can alleviate certain financial burdens for patients, patients still need to fully communicate with their doctors before receiving treatment to understand the usage, side effects and possible efficacy of the drugs in order to make the most appropriate treatment decision.

Reference materials:https://en.wikipedia.org/wiki/Neratinib